UCB (OTCMKTS:UCBJY) Stock Rating Upgraded by Zacks Research

UCB (OTCMKTS:UCBJY) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the stock. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, UCB has an average rating of “Buy”.

UCB Stock Performance

UCBJY opened at $132.20 on Tuesday. UCB has a twelve month low of $106.24 and a twelve month high of $168.76. The business’s 50 day moving average is $142.79 and its 200-day moving average is $146.99. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.